Featured Patent Applications of the Week: March 15, 2019

MaxVal’s weekly column provides insights into recently published patent applications for some of the most innovative companies in the world.

In this post, we take you through some of the recent patent applications filed by Facebook, Intel, Google, Qualcomm, Amazon, Apple, Medtronic, Novartis, Boston Scientific, Abbott, Merck, and Roche.

Continue reading

MaxVal and Aistemos Extend Litigation Data Partnership

Aistemos’s advanced patent analysis software, Cipher, now includes MaxVal’s international patent litigation data

Continue reading

Featured Patents of the Week: March 13, 2019

In this post, we take you through some of the recent patents from Apple, Google, Qualcomm, Amazon, Intel, Facebook, Merck, Medtronic, Novartis, Pfizer, and Roche.  

Continue reading

Featured Patents and Applications of the Week: March 12, 2019

MaxVal’s new semiweekly column provides insights into recently issued patents and applications for some of the most innovative companies in the world.

In this post, we take you through some of the recent patents and applications from Intel, Apple, Google, Amazon, Facebook, Merck, Medtronic, Novartis, Pfizer, and Roche.  

Continue reading

Additional Patent Term Adjustment Potentially Available for Patents with IDS

Additional Patent Term Adjustment (PTA) may be available for some cases where an Information Disclosure Statement (IDS) was filed after a reply. Recently in Supernus Pharmaceuticals, Inc. v. Iancu, the U.S. Court of Appeals for the Federal Circuit held that the USPTO had incorrectly reduced the PTA based on applicant delay for a period of time during which there was no action that the applicant could take to conclude prosecution of the patent.

Continue reading

2018 Year In Review: FDA Drug Approvals

The pharma industry and US FDA will reflect on a record breaking 2018 for drug approvals. The Center for Drug Evaluation and Research (CDER) approved 59 new drugs last year which is a significant increase from previous years (FIG. 1; area plots). In the last 10 years, the FDA has approved 271 novel drugs and 85 biologics (FIG. 1, line plots). The new approvals for 2018 includes 42 new molecular entities and 17 new biologics. Small molecules dominate the list contributing to 64% of the approved drugs, while antibodies represent another 20%. There was a 40% increase in approvals of cancer therapies as compared to 2017. Increased approval trends were observed towards the end of the year with the last quarters accounting for more than 70% of the approved drugs. Oral dosage forms, such as tablets and capsules, accounted for greater than 80% of approved drugs (FIG. 2).

Continue reading

2018 Year In Review: Patent Publication Trends

We have published the second volume of our newsletter which gives an insight into the patent publication trends of the past year. The classification has been done based on countries, companies, and more. The graphical representation of the various statistical values aim to provide an overview of how the patenting scenario has changed and the technologies which show promise for patents.

Continue reading

Three Key Areas Shaping The Landscape Of Hypertension Management Devices

Cardiovascular diseases claim 17.7 million lives annually, and account for 31% of all global deaths. Cardiovascular diseases can broadly be divided into the following types: i) hypertensive heart diseases, ii) coronary heart diseases, iii) inflammatory heart disease, iv) rheumatic heart diseases, v) stroke and vi) other cardiovascular diseases.

Continue reading

MaxVal Announces Support for USPTO’s Authentication Changes

MaxVal announces that all of our software products and services now support the USPTO’s upcoming Private PAIR changes.

Continue reading

Hot Topics in Tech | December 2018 Newsletter

In the December issue of the “Hot Topics in Tech” newsletter series, we take a glance at how mobile devices have transformed healthcare and became a crucial component in the medical field.

Continue reading